SER-287 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	2

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03759041 (ClinicalTrials.gov)	December 19, 2018	27/11/2018	A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis	ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis	Ulcerative Colitis	Drug: Vancomycin Pre-Treatment;Drug: Placebo for Vancomycin Pre-Treatment;Drug: SER-287;Drug: Placebo for SER-287	Seres Therapeutics, Inc.	NULL	Terminated	18 Years	80 Years	All	203	Phase 2	United States;Canada
2	NCT02618187 (ClinicalTrials.gov)	January 13, 2016	20/11/2015	A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis	A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis	Ulcerative Colitis	Drug: SER-287;Drug: Placebo;Drug: Placebo Pre-Treat;Drug: Vancomycin Pre-Treat	Seres Therapeutics, Inc.	NULL	Completed	18 Years	75 Years	All	58	Phase 1	United States